Anchor Capital Advisors LLC Acquires Shares of 3,408 Merck & Co., Inc. (NYSE:MRK)

Anchor Capital Advisors LLC acquired a new stake in Merck & Co., Inc. (NYSE:MRK) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 3,408 shares of the company’s stock, valued at approximately $287,000.

Several other institutional investors have also added to or reduced their stakes in MRK. Nuveen Asset Management LLC lifted its stake in shares of Merck & Co., Inc. by 6,517.4% in the second quarter. Nuveen Asset Management LLC now owns 24,307,332 shares of the company’s stock valued at $2,038,169,000 after buying an additional 23,940,007 shares in the last quarter. BlackRock Inc. lifted its stake in shares of Merck & Co., Inc. by 2.3% in the second quarter. BlackRock Inc. now owns 191,863,408 shares of the company’s stock valued at $16,087,745,000 after buying an additional 4,397,580 shares in the last quarter. Invesco Ltd. lifted its stake in shares of Merck & Co., Inc. by 18.4% in the second quarter. Invesco Ltd. now owns 18,309,138 shares of the company’s stock valued at $1,535,222,000 after buying an additional 2,843,458 shares in the last quarter. Schroder Investment Management Group lifted its stake in shares of Merck & Co., Inc. by 67.7% in the second quarter. Schroder Investment Management Group now owns 6,381,329 shares of the company’s stock valued at $535,075,000 after buying an additional 2,576,060 shares in the last quarter. Finally, UBS Asset Management Americas Inc. lifted its stake in shares of Merck & Co., Inc. by 20.4% in the second quarter. UBS Asset Management Americas Inc. now owns 11,661,412 shares of the company’s stock valued at $977,809,000 after buying an additional 1,972,587 shares in the last quarter. 75.02% of the stock is currently owned by hedge funds and other institutional investors.

In related news, EVP Richard R. Deluca sold 6,427 shares of the firm’s stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $85.09, for a total transaction of $546,873.43. Following the completion of the sale, the executive vice president now owns 103,223 shares in the company, valued at $8,783,245.07. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.27% of the company’s stock.

NYSE MRK opened at $82.20 on Tuesday. Merck & Co., Inc. has a 52-week low of $70.12 and a 52-week high of $87.35. The company has a 50-day simple moving average of $83.68 and a 200 day simple moving average of $82.35. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.92 and a current ratio of 1.21. The company has a market capitalization of $211.44 billion, a PE ratio of 18.94, a price-to-earnings-growth ratio of 1.93 and a beta of 0.53.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, July 30th. The company reported $1.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.16 by $0.14. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 43.34%. The business had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $10.94 billion. During the same quarter last year, the company posted $1.06 earnings per share. The firm’s quarterly revenue was up 12.4% compared to the same quarter last year. As a group, analysts forecast that Merck & Co., Inc. will post 4.91 EPS for the current fiscal year.

A number of research analysts have weighed in on MRK shares. Credit Suisse Group reaffirmed a “buy” rating and issued a $95.00 price objective on shares of Merck & Co., Inc. in a research note on Wednesday, August 7th. ValuEngine lowered shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. Societe Generale set a $105.00 price target on shares of Merck & Co., Inc. and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Svb Leerink initiated coverage on shares of Merck & Co., Inc. in a research report on Friday, August 16th. They set an “outperform” rating and a $103.00 price target on the stock. Finally, Mizuho reissued a “buy” rating and set a $97.00 price target on shares of Merck & Co., Inc. in a research report on Friday, October 18th. One analyst has rated the stock with a sell rating, three have issued a hold rating and fourteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $94.00.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: Asset Allocation

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.